-
Anle138b Clinical Phase 1 Studies: Food Effect, Safety and Tolerability as well as Pharmacokinetics in Parkinson´s Disease Patients
… finalize ongoing plans for disease modification studies in multiple system atrophy (MSA) and Parkinson’s. … Therapeutic Development … …
-
Sylvie Ramboz, PhD
… and characterizing pre-clinical models of central nervous system (CNS) diseases. Dr. Ramboz brings more than 20 years … operational and business development of spinal muscular atrophy, muscular dystrophies, Huntington and Parkinson …
-
The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for Parkinson’s Disease
May 4, 2015
… look forward to reporting results from our ongoing Phase 1 multiple ascending dose study of PRX002 in patients with … disease, dementia with Lewy bodies, and multiple system atrophy, which collectively are termed synucleinopathies. …
-
U.S. Department of Veterans Affairs Expands Benefits for People with Parkinsonism Associated with Agent Orange Exposure
June 11, 2021
… Parkinson’s disease dementia, dementia with Lewy bodies, multiple system atrophy and more. Vietnam War veterans with Parkinsonism who …
-
-
A Roadmap for Alpha-Synuclein
November 30, 2018
… this protein, such as dementia with Lewy bodies and multiple system atrophy. You can learn more about the working group and read …